Work

De Novo Psoriasis Following Belatacept Therapy in Transplant Recipients: Case Series

Year: 2025

Type: article

Abstract: Belatacept is an immunoglobulin fusion protein that selectively inhibits T-cell activation by blocking CD28 signaling and disrupting CTLA4 (cytotoxic T-lymphocyte associated protein 4) and CD80/CD86 interactions on immune cells.With its favorable cardiovascular and renal profile, belatacept is increasingly utilized as an alternative agent to prevent organ rejection in kidney transplant recipients (KTRs) [ 1 ].While generally well-tolerated, belatacept has been associated with psoriasis, with two cases of psoriasis reactivation and one case of de novo psoriasis reported in the current literature [ 2,3 ].Cicora et al. reported two transplant patients who developed psoriasis reactivation after initiating belatacept [ 2 ].Another case involved a post-renal transplant patient on mycophenolic acid for maintenance therapy, who developed de novo psoriatic plaques after starting belatacept.The patient's psoriasis resolved completely several weeks after discontinuing belatacept, suggesting a potential causal relationship [ 3 ].Our transplant service has observed six patients on belatacept who developed de novo psoriasis, suggesting this may be underreported and underrecognized.This case series defines the patient characteristics and treatment approaches in patients with transplant-associated psoriasis.

Source: Clinical Transplantation

DOI: 10.1111/ctr.70416

Authors: Grace Y. Im, Kellyn E. Mckee, R. Hal Flowers, Angie G. Nishio Lucar, Swati Rao

Institutions: University of Virginia Health System, University of Virginia

Language: English

Topic: Renal Transplantation Outcomes and Treatments

Subfield: Transplantation

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,550